A Phase 1 interventional study of CC-97540 and Fludarabine in Multiple Sclerosis and Myasthenia Gravis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 34 sites in 6 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Multiple Sclerosis by Bristol-Myers Squibb — 4 open to participants now, 7 under way, 1 of them phase 3. Multiple Sclerosis · Bristol-Myers Squibb.
Among the 18 studies in Multiple Sclerosis by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 14th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 18 studies in Multiple Sclerosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Celgene · Sites in United States, Australia, Canada and 4 more countries
Ages 18–70
Bristol-Myers Squibb · Sites in United States, Australia, Italy and 8 more countries
Ages 10–17
Bristol-Myers Squibb · Sites in United States, Germany
Women only
By country, each count listing its studies:
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2001; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 191 across the 12 interventional studies, 450 across the 5 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
2 of the studies in Multiple Sclerosis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06782490CelgeneA Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | 2027-05-26 |
| NCT06220201Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Multiple Sclerosis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Relapsing forms of Multiple Sclerosis (RMS) - Cohort 1.
i) Participants must have an Expanded Disability Status Scale (EDSS) of ≥ 3.0 and ≤ 5.5.
ii) Participants must have a diagnosis of Multiple Sclerosis (MS) with MS or conversion to active secondary progressive multiple sclerosis (aSPMS), and worsening of disease within 12 months prior to Screening and while on treatment with a high-efficacy DMT for at least 6 months.
- Progressive forms of MS - Cohort 2.
i) Participants must have an EDSS ≥ 3.0 and ≤ 6.0.
ii) Participants must have a diagnosis of primary progressive multiple sclerosis (PPMS) that is treatment-resistant or diagnosis of inactive secondary progressive multiple sclerosis (iSPMS).
- Myasthenia Gravis - Cohort 3
i)MGFA classification of II-IV at screening
ii) Documentation of autoantibodies against AChR or MuSK (historical or at Screening)
iii) Refractory disease defined as disease activity on at least 2 , including , NSIs, or biologics.
iv) Has had thymectomy, only if indicated according to current guidelines.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide
Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide
Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide
Specified dose on specified days
Also known as: BMS-986353
Specified dose on specified days
Specified dose on specified days
Number of participants with adverse events (AEs)
Time frame: Up to week 104
Number of participants with serious adverse events (SAEs)
Time frame: Up to week 104
Number of participants with adverse events of special interest (AESIs)
Time frame: Up to week 104
Number of participants with laboratory test result abnormalities
Time frame: Up to week 104
Number of participants with imaging abnormalities
For Cohorts 1 and 2
Time frame: Up to week 104
Number of participants with dose-limiting toxicities (DLTs)
Time frame: Up to week 104
Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period
Time frame: Up to week 104
Number of participants meeting no evidence of disease activity (NEDA) criteria
Time frame: Up to week 104
Number of participants with confirmed disability progression per Expanded Disability Status Scale (EDSS)
Time frame: Up to week 12
Annualized relapse rate
Time frame: Up to week 104
Change from baseline in magnetic resonance imaging (MRI) metrics
MRI metrics assessed are 1) number of gadolinium-enhancing T1 lesions and 2) total number of new or enlarging hyperintense T2-weigted lesions
Time frame: Up to week 104
Number of participants with disability improvement confirmed per EDSS
Time frame: Up to week 12
Maximum observed blood concentration (Cmax)
Time frame: Up to week 104
Time of maximum observed blood concentration (Tmax)
Time frame: Up to week 104
Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))
Time frame: Up to week 104
Time to last measurable chimeric antigen receptor (CAR T) concentrations (Tlast)
Time frame: Up to week 104
Number of participants with at least 2 points improvement for at least 4 weeks in Myasthenia Gravis activities of daily living (MG-ADL) score
For Cohort 3
Time frame: Up to week 26
Number of participants with at least 3 point improvement in Myasthenia Gravis composite (MG-C) score
For Cohort 3
Time frame: Up to week 26
Number of participants with at least 3 point improvement in quantitative Myasthenia Gravis (QMG) score
For Cohort 3
Time frame: Up to week 26
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Mar 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.
Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's planned 39 months is above that.
Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zolacabtagene autoleucel
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company →